Metraipolis › archive › dc_660be97553c8

Indobufen Versus Aspirin Plus Clopidogrel in Patients After Coronary Stenting in Patients With Diabetes: A Post Hoc Analysis of the OPTION Trial — Europe PMC PMID:40910183

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40910183
DOI
10.1111/1753-0407.70152
License (as archived)
solo-consultazione
Archived
2026-11-10T04:59:06.827Z
SHA-256 of the archived text
b3baf203c08786928ead18b0ea41c7fd13f0de7e268936be0127e77e60b61b91
Stable URL of this page
https://metraipolis.com/documento/dc_660be97553c8

How to cite

Indobufen Versus Aspirin Plus Clopidogrel in Patients After Coronary Stenting in Patients With Diabetes: A Post Hoc Analysis of the OPTION Trial — Europe PMC PMID:40910183 — Europe PMC (en), https://europepmc.org/article/MED/40910183 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_660be97553c8 (Metraipolis archive dc_660be97553c8, sha256 b3baf203c08786928ead18b0ea41c7fd13f0de7e268936be0127e77e60b61b91)
BibTeX
@misc{dc660be97553c8,
  title = {Indobufen Versus Aspirin Plus Clopidogrel in Patients After Coronary Stenting in Patients With Diabetes: A Post Hoc Analysis of the OPTION Trial — Europe PMC PMID:40910183},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40910183},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_660be97553c8; sha256 b3baf203c08786928ead18b0ea41c7fd13f0de7e268936be0127e77e60b61b91},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40910183. Agents can read the archived copy with the MCP tool read_document.